Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interventional, Randomised, Double-blind, Parallel-group Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder

NCT02919501 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT02919501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02919501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interventional, Randomised, Double-blind, Parallel-group Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder
Lead sponsor
H. Lundbeck A/S
Phase
Phase 2
Overall status
Completed
Start date
September 27, 2016
Completion date
April 27, 2017
Enrollment
55 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major